Cite
APA Citation
Orliaguet, M., Boisramé, S., Eveillard, J., Pan‐Petesch, B., Couturier, M., Rebière, V., Guillerm, G., Le Bousse‐Kerdiles, M., Misery, L., Lippert, E., & Ianotto, J. (2020). pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms. EJHaem, 1(1), 350–352. http://access.bl.uk/ark:/81055/vdc_100113633358.0x000003